Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Stem Cells Int ; 2022: 6379161, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35935180

RESUMO

Autoimmune diseases, chronic in nature, are generally hard to alleviate. Present long-term treatments with available drugs such as steroids, immune-suppressive drugs, or antibodies have several debilitating side effects. Therefore, new treatment options are urgently needed. Stem cells, in general, have the potential to reduce immune-mediated damage through immunomodulation and T cell regulation (T regs) by inhibiting the proliferation of dendritic cells and T and B cells and reducing inflammation through the generation of immunosuppressive biomolecules like interleukin 10 (IL-10), transforming growth factor-ß (TGF-ß), nitric oxide (NO), indoleamine 2,3-dioxygenase (IDO), and prostaglandin E2 (PGE2). Many stem cell-based therapeutics have been evaluated in the clinic, but the overall clinical outcomes in terms of efficacy and the longevity of therapeutic benefits seem to be variable and inconsistent with the postulated benefits. This emphasizes a greater need for building robust preclinical models and models that can better predict the clinical translation of stem cell-based therapeutics. Stem cell therapy based on MSCs having the definitive potential to regulate the immune system and control inflammation is emerging as a promising tool for the treatment of autoimmune disorders while promoting tissue regeneration. MSCs, derived from bone marrow, umbilical cord, and adipose tissue, have been shown to be highly immunomodulatory and anti-inflammatory and shown to enhance tissue repair and regeneration in preclinical models as well as in clinical settings. In this article, a review on the status of MSC-based preclinical disease models with emphasis on understanding disease mechanisms in chronic inflammatory disorders caused by exaggerated host immune response in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) was carried out. We also emphasized various factors that better predict the translation of stem cell therapeutic outcomes from preclinical disease models to human patients.

2.
Bioresour Technol ; 152: 572-5, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24360518

RESUMO

Green algae, Monoraphidium sp. T4X, was isolated locally, in New Delhi, India and identified as a potential source of biofuel. The study focuses on the effect of nutritional amendments and their uptake rates with respect to growth and change in fatty acid composition of the species. The lipid productivity and fatty acid profile were investigated and compared under six different nitrogen concentrations. Of the tested concentrations, cultures with nitrate concentration 0.36 g/l exhibited higher lipid productivity (0.18 g/l/day) with optimum content of all fatty acid compositions (SFA=37.22, MUFA=39.19, PUFA=23.60) with appropriate biodiesel properties. The right phase for harvesting microalgae was also investigated on the basis of the growth curve.


Assuntos
Clorófitas/metabolismo , Ácidos Graxos/metabolismo , Nitrogênio/farmacologia , Biomassa , Clorófitas/efeitos dos fármacos , Clorófitas/crescimento & desenvolvimento , Cinética , Nitratos/farmacologia , Nitrogênio/metabolismo , Fósforo/metabolismo , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...